• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form 3 filed by new insider Chung Ho Fai

    6/16/26 6:04:07 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care
    Get the next $NIVF alert in real time by email
    SEC FORM 3/ASEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Chung Ho Fai

    (Last)(First)(Middle)
    C/O 1/F, PIER 2, CENTRAL

    (Street)
    HONG KONG

    (City)(State)(Zip)

    HONG KONG

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/18/2026
    3. Issuer Name and Ticker or Trading Symbol
    NewGenIvf Group Ltd [ NIVF ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    03/23/2026
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Financial Officer
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    Remarks:
    This Amendment on Form 3/A is being filed solely to correct the inadvertent error in the original Form 3 filed on March 23, 2026. Except for this correction, no other changes are made to the original filing.
    No securities are beneficially owned.
    /s/ Ho Fai Chung06/15/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $NIVF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NIVF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NIVF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 3 filed by new insider Chung Ho Fai

    3/A - NewGenIvf Group Ltd (0001981662) (Issuer)

    6/16/26 6:04:07 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    Large owner Hrt Financial Lp sold $50,722 worth of shares (64,945 units at $0.78), decreasing direct ownership by 78% to 18,134 units (SEC Form 4)

    4 - NewGenIvf Group Ltd (0001981662) (Issuer)

    6/8/26 3:11:25 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    Director Siu Wing Fung Alfred exercised 56,851 units of Class B Ordinary Shares at a strike of $0.00, increasing direct ownership by 189,503% to 56,881 units (SEC Form 4)

    4 - NewGenIvf Group Ltd (0001981662) (Issuer)

    6/5/26 11:14:50 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NewGen Issues 3,666,667 New Shares in Connection with Strategic K25.ai Acquisition, Reaches Milestone of US$7.6 Million Market Capitalization

    BANGKOK, June 22, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company") today announced that NewGen’s total outstanding shares now stand at 10,073,535 following share issuances in connection with its strategic share purchase agreements to acquire a 10% equity interest in K25.ai. The Company’s market capitalization reached US$7,631,710 on June 18, 2026, providing a solid foundation for future growth. Management views this market capitalization as representing a substantial discount to the Company’s net asset value of approximately US$25.98 million as of December 31, 2025. The balance sheet has been further strengthened by the Company’s subsequent US$10 m

    6/22/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Increases K25.ai Ownership to 10% in Closed Pre-A Round at US$100 Million Valuation with Total US$10 Million Invested

    K25.ai to complete its US$10 million Pre-A at a US$100 million valuation and is now raising its Series A to accelerate product launch and regional expansion NewGen's expanded stake and exclusive Asia-Pacific agency rights deepen its strategic participation in K25.ai's next phase of growth BANGKOK, June 18, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a technology-driven, diversified growth company, today announced that it has executed an agreement for a further US$4 million strategic investment in K25.ai. The transaction completes K25.ai's US$10 million Pre-A round at a US$100 million valuation and, upon completion and satisfaction of the ap

    6/18/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGen Eliminates Convertible Note and Warrant Overhang with a Significant Investor, Enters Into Settlement Agreement Strengthening Capital Structure

    NewGen to repurchase all outstanding convertible notes and warrants previously held by a significant investor in move to strengthen its capital structure Settlement to eliminate potential dilution from convertible notes and warrants Company views that this will position the Company's market capitalization to be undervalued relative to net assets BANGKOK, June 16, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company") today announced that it has entered into a Repurchase and Forbearance Agreement (the "Settlement Agreement") with a significant investor (the "Investor"). Under the terms of the Settlement Agreement, NewGen will repurchase all outstandi

    6/16/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Leadership Updates

    Live Leadership Updates

    View All

    NewGen Doubles Down on K25.ai with Additional US$4 Million Stake and Adopts Digital Asset Treasury Strategy

    NewGen's 6% Stake in K25.ai Now Valued at US$6 MillionCompany will Leverage Expertise of K25.ai's Andy Cheung to Develop Digital Asset Treasury Strategy BANGKOK, June 04, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a technology-driven, diversified growth company, today announced it has exercised its top-up option to acquire an additional 4% equity interest in AI-native livestreaming prediction market platform K25.ai, raising its total holding to 6%. The additional US$4 million investment, which supplements an initial US$2 million investment announced in May 2026, is split evenly between cash and newly issued NewGen Class A ordinary shares.

    6/4/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts

    BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (("NewGen" or the "Company, NASDAQ:NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today announced the appointment of award-winning Web3 legal and regulatory specialist Joshua Chu as Senior Counsel to lead the Group's tokenization strategy, alongside the formal engagement of Evident Capital, Hong Kong's first fully integrated, SFC-licensed tokenization and alternative assets platform, to support the launch of NIVF's inaugural tokenized bond issuance of up to USD 30 million targeted for completion by the first quarter of 2026. As S

    1/21/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    NewGenDigital Appointed as SAXA Inc.'s Agent for Tokenization of US$100 Million of Gold-backed Assets

    Service agreement with SAXA, Inc. appoints NewGenDigital as SAXA's worldwide tokenization agent, strengthening cooperation between the two companies ahead of proposed reverse merger Value of tokenized assets could be expanded to US$1 billion under the terms of the agreement; NewGenDigital to earn 5% commission on assets sold BANGKOK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ:NIVF) ("NewGen" or the "Company"), a tech-forward, diversified, multi-jurisdictional high-growth entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that its subsidiary, NewGenD

    11/5/25 9:00:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hrt Financial Lp bought $32,000 worth of shares (34,756 units at $0.92), increasing direct ownership by 72% to 83,079 units (SEC Form 4)

    4 - NewGenIvf Group Ltd (0001981662) (Issuer)

    6/4/26 4:08:25 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    Large owner Hrt Financial Lp bought $161,919 worth of shares (165,534 units at $0.98) (SEC Form 4)

    4 - NewGenIvf Group Ltd (0001981662) (Issuer)

    5/27/26 1:19:20 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    SEC Filings

    View All

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    6/22/26 9:41:59 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    6/18/26 8:30:09 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 6-K filed by NewGenIvf Group Limited

    6-K - NewGenIvf Group Ltd (0001981662) (Filer)

    6/16/26 8:30:01 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Financials

    Live finance-specific insights

    View All

    NewGen Provides Update on Fiscal Year 2025 Results and Strategic Progress

    NewGen records strong balance sheet with total assets of US$32.7 million Net profit attributable to shareholders of the Company of US$9.9 million BANGKOK, May 04, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group (NASDAQ:NIVF) ("NewGen" or the "Company"), a technology-driven, diversified growth company, today outlined several highlights of its fiscal year 2025 results and the steady progress of its continued strategic transformation. More information on NewGen's results can be found in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2025, (the "2025 Annual Report") which was filed with the U.S. Securities and Exchange Commission (the "SEC") in April 2026. The ful

    5/4/26 8:30:00 AM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    $NIVF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    12/5/24 8:23:57 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    11/13/24 9:19:27 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by NewGenIvf Group Limited

    SC 13G - NewGenIvf Group Ltd (0001981662) (Subject)

    10/10/24 3:39:26 PM ET
    $NIVF
    Misc Health and Biotechnology Services
    Health Care